嵌合抗原受体基因修饰T细胞治疗胶质母细胞瘤的研究进展  

Research Progress of Chimeric Antigen Receptor Gene Modified T Cell in Treatment of Glioblastoma

作　　者：刘磊[1] 董星辰 梁家政 宋旭东 丁涟沭[1] LIU Lei;DONG Xingchen;LIANG Jiazheng;SONG Xudong;DING Lianshu(Department of Neurosurgery,the Affiliated Huai′an No.1 People′s Hospital of Nanjing Medical University,Huai′an 223001,China)

机构地区：[1]南京医科大学附属淮安第一医院神经外科,江苏淮安223001

出　　处：《医学综述》2022年第5期905-909,共5页Medical Recapitulate

基　　金：国家自然科学基金(21775051);江苏省卫生健康委科研项目(ZD2021051);淮安市“533英才工程”科研项目(HAA201741)。

摘　　要：胶质母细胞瘤(GBM)是成人最常见、最致命的原发性脑肿瘤。目前GBM的常规治疗包括手术、局部和全身化疗、放疗等,但治疗效果常不理想。嵌合抗原受体基因修饰T细胞(CAR-T细胞)治疗作为一种新的过继性免疫疗法,已经在血液肿瘤治疗中取得了较好的临床效果。CAR-T细胞可穿过血脑屏障,且不通过抗原呈递、不依赖主要组织相容性复合物即可识别预定义的肿瘤表面抗原。在GBM体外试验中,CAR-T细胞治疗的效果显著,但其临床应用仍存在诸多挑战。Glioblastoma(GBM)is the most common and fatal primary brain tumor in adults.At present,the conventional treatment of GBM includes surgery,local and systemic chemotherapy,radiotherapy and so on,but the therapeutic effect is often not ideal.Chimeric antigen receptor gene modified T cell(CAR-T cell)therapy as a new adoptive immunotherapy,has achieved good clinical results in the treatment of hematological malignancies.CAR-T cell can cross the blood-brain barrier and recognize predefined tumor surface antigens without antigen presentation or relying on major histocompatibility complexes.In GBM in vitro test,CAR-T cell therapy has a significant effect,but its clinical application still faces many challenges.

关 键 词：胶质母细胞瘤 嵌合抗原受体基因修饰T细胞 过继性免疫治疗 

分 类 号：R739.41[医药卫生—肿瘤]